Overview
- Genmab and AbbVie reported that adding epcoritamab to standard R‑CHOP reduced the risk of disease progression or death by 51% versus R‑CHOP alone in a randomized phase 3 study of newly diagnosed diffuse large B‑cell lymphoma.
- The trial met its primary goal in the higher‑risk group and showed the same 51% PFS benefit in the broader enrolled population, suggesting a consistent effect across patients with International Prognostic Index scores in the study range.
- Epcoritamab is a bispecific, T‑cell engaging antibody that redirects a patient’s T cells to attack lymphoma cells and is jointly developed by Genmab and AbbVie.
- The companies said the combination’s safety profile was generally consistent with known effects of epcoritamab and R‑CHOP, but detailed adverse‑event data were not included in the topline announcement.
- Investors reacted quickly with Genmab shares jumping about 11% and AbbVie shares rising about 1.5%, and the companies said they will present the data at a future medical meeting and share results with health authorities, which could influence first‑line care if regulators review the full data.